Stage IIA Skin Melanoma Treatment With ECHO-7 Oncolytic Virus Rigvir

Ingrīda Čēma, Regīna Kleina, Simona Doniņa, Sergejs Isajevs, Tatjana Zablocka, Agnija Rasa (Coresponding Author), Pēteris Alberts

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
18 Downloads (Pure)

Abstract

Melanoma is a global problem due to the rising numbers of skin melanoma cases. Current treatment guidelines for patients with stage IIA melanoma recommend only observation after surgery. In this report, the authors describe a patient with stage IIA skin melanoma treated with surgery and Rigvir virotherapy. Two years after the patient discovered a brown spot on the right cheek, surgery was indicated because the mass had started to ulcerate. Rigvir virotherapy was applied both before and after surgery. Observations made more than 7 years after surgery indicated no signs of disease progression. This case report illustrates an early treatment approach. Neoadjuvant treatment for early-stage melanoma is gaining more interest in both scientific and medical communities; therefore, the authors believe it is relevant to share their observations.

Original languageEnglish
Pages (from-to)139-144
Number of pages6
JournalThe Permanente journal
Volume26
Issue number3
DOIs
Publication statusPublished - 14 Sept 2022

Keywords*

  • case report
  • ECHO-7 virus
  • melanoma
  • oncolytic virus
  • peritumoral administration
  • Rigvir
  • virotherapy

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Stage IIA Skin Melanoma Treatment With ECHO-7 Oncolytic Virus Rigvir'. Together they form a unique fingerprint.

Cite this